Company news: GlaxoSmithKline

Share this article:
GlaxoSmithKline is readying another round of R&D cuts and giving its Research Triangle Park workforce a haircut, with plans to eliminate positions at its Neurosciences Medicine Development Center, according to the News & Observer of Raleigh, NC. Less than 50 R&D jobs are being eliminated nationwide, with fewer than half of those coming from Research Triangle Park and Philadelphia emerging largely unscathed. It's a drop in the bucket after years of deep cuts at the company, which has cut 22,000 jobs worldwide between 2007 and 2010, the newspaper reported.
Share this article:

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.